Document:

EX-10.8

 Exhibit 10.8 

Confidential Treatment Requested 

AMENDED AND RESTATED 

EXCLUSIVE LICENSE AGREEMENT 

This Amended and Restated Exclusive Agreement (this “Agreement”) is made and is effective as of June 2, 2014 (the
“Effective Date”) between The UAB Research Foundation (“UABRF”) and Vaxin Inc. (the “Licensee”) and amends and restates in its entirety the Exclusive License Agreement between the Parties dated March 1, 1998 (the
“Original License”). 
 RECITALS 

WHEREAS, UABRF owns all right, title and interest in the intellectual property described in UABRF intellectual property disclosures numbered
U1996-0083, U1997-0087, U2003-0015, U2003-0016, U2003-0017, U2003-0039, which were developed and disclosed to UABRF by De-chu Tang, while employed by the University of Alabama at Birmingham (the “Inventor”), and are embodied in the
Licensed Patents, has the right to grant licenses to the same and desires to have the same developed and commercialized to benefit the public; and 

WHEREAS, the Licensee is engaged in the business of discovering, developing, licensing, manufacturing, marketing and selling pharmaceutical
products and related activities; and in the course of such business is engaged in the commercialization of pharmaceutical products which are based in whole or in part on technologies found in the patents which protect the above listed intellectual
property disclosures and desires to obtain a license to the Licensed Patents upon the terms and conditions set forth in this Agreement. 

NOW, THEREFORE, in consideration of the premises described above and the mutual promises and agreements set forth in this Agreement, the
Parties agree as set forth below. 
 ARTICLE 1 

DEFINITIONS 

The Definitions used in this Agreement are set forth below. 
  

	1.1	“Affiliate” means any Person that directly or indirectly controls, is controlled by, or is under common control with a Party. “Control” means (i) the beneficial ownership of at least fifty
percent (50%) of the voting securities of a Person with voting equity, or (ii) the power to direct or cause the direction of the management or policies of a Person. 

 

	1.2	“Agreement” means this agreement, as amended from time to time in accordance with the terms and conditions set forth in this agreement. 

 

	1.3	“Applicable Law” means all laws, statutes and regulations promulgated by all Regulatory Authorities and all Governmental Authorities. 

 

	1.4	“Development and Commercialization Plan” means development, manufacturing, marketing and commercialization activities proposed to be undertaken by the Licensee with respect to the Licensed Patents as set forth
on attached Exhibit B. 

  
 1 of 27 

 Confidential Treatment Requested 

 

	1.5	“Disclaimed Licensed Patent(s)” means any Licensed Patent in respect of which the Licensee decides not to pursue protective rights, undertake, or be responsible for, the payment of Protection Expenses, as
described in Section 4.1(e) and (f) of this Agreement. 

  

	1.6	“First Commercial Sale” means the first Sale of a Licensed Product to a Third Party. 

  

	1.7	“For Value” means any consideration, remuneration or benefit of any kind, whether received directly or indirectly, including, but not limited to, cash, equity, debt, preferential treatment, including waiver,
rebate, discount, etc. 

  

	1.8	“Governmental Authorities” means, with respect to each country or jurisdiction, all legislative and governmental authorities, bodies, commissions, agencies or other instrumentalities of such country or
jurisdiction. 

  

	1.9	“Infringement Notice” is defined in Section 7.1 of this Agreement. 

  

	1.10	“Inventor” is defined in the first recital of this Agreement. 

  

	1.11	“Licensed Field of Use” means any diagnostic, vaccine or therapeutic use or methods. 

  

	1.12	“Licensed Patents” means (a) the patents and/or patent applications set forth on attached Exhibit A, (b) any foreign patent applications based thereon, (c) all patents proceeding from such
domestic and foreign patent applications, (d) all claims of continuations-in-part that are entitled to the benefit of the priority date of the parent Licensed Patent and are enabled by subject matter that is disclosed in the parent Licensed
Patent, and (e) all divisionals, continuations, reissues, reexaminations and extensions of any patent or patent application described in (a) – (d) above. Licensed Patents does not include any patent and/or patent application that
relates to a Disclaimed Licensed Patent. 

  

	1.13	“Licensed Product” means any product or part thereof, process or service, the development, manufacture, use, import, export, offer for sale or sale of which is covered by, or which cannot be undertaken or
completed without infringing, a Valid Patent Claim set forth in any Licensed Patent. 

  

	1.14	“Licensed Territory” means those countries in which patent coverage is pending or has been granted. 

  

	1.15	“Management Activities” means any and all Protection Activities and any other steps deemed necessary and reasonable to commercialize the Disclaimed Licensed Patents. 

 

	1.16	“Net Sales” means the gross amount set forth on the invoice relating to any Sale of a Licensed Product, less (a) discounts actually allowed, (b) rebates, price reductions, rebates to social and
welfare systems, charge backs, government mandated and similar rebates, (c) credits for claims, allowances, retroactive price reductions or returned goods, (d) prepaid freight and insurance, (e) customs duties, sales taxes or other
governmental charges actually paid in connection with such Sale (but excluding income tax). Where a Licensed Product is not used, transferred or exchanged For Value, the Net Sales will be the net invoice price of products of similar kind and
quality, sold or transferred For Value 

  
 2 of 27 

 Confidential Treatment Requested 

 

	 	
at similar quantities, currently being offered by the Licensee, a Sublicensee or by other manufacturers. Where there is no comparable sale or transfer For Value, the Net Sale will be the
Licensee’s or Sublicensee’s cost of manufacture, determined by the Licensee’s or Sublicensee’s customary accounting procedures, plus a percentage commensurate with industry standards as mutually agreed upon between the Parties at
the time of identification. 

  

	1.17	“Non-Commercial Research Purposes” means any use and practice for academic research and educational purposes. 

  

	1.18	“Non-Royalty Income” means anything received For Value that is cash or a cash equivalent that is not calculated upon a percentage of Net Sales, including, but not limited to, fees and advances. For purposes of
clarity, the purchase by a Sublicensee of shares of the Licensee as specified in a sublicense agreement shall be considered a non-cash payment to the Licensee and is therefore not considered Non-Royalty Income. 

 

	1.19	“Parties” means UABRF and the Licensee and each of them individually is a “Party.” 

  

	1.20	“Person” means an individual, corporation, partnership, trust, business trust, association or any other entity with a separate legal identity, including the Parties. 

 

	1.21	“Proprietary Information” is defined in Section 8.4. 

  

	1.22	“Protection Activities” means taking all actions deemed reasonably necessary to protect the Licensed Patents, including, but not limited to, obtaining, filing for, securing, pursuing, prosecuting, continuing
or maintaining, and defending the patents and patent applications, subject to the terms set forth herein. 

  

	1.23	“Protection Expenses” means all legal fees, costs and expenses reasonably incurred by UABRF in the performance of the Protection Activities, such fees, costs and expenses to be documented by written invoice.

  

	1.24	“Regulatory Authority” means, with respect to any particular country or jurisdiction, the Governmental Authority with the primary responsibility for the evaluation or approval of pharmaceutical products before
such products can be tested, marketed, promoted, distributed or sold in such country, including Governmental Authorities that have jurisdiction over the pricing of such products. The term Regulatory Authority includes the Federal Food and Drug
Administration of the United States. 

  

	1.25	“Representative(s)” means, with respect to each Party and their Affiliates, all trustees, directors, officers, employees, agents and advisors. 

 

	1.26	“Sale or Sales” means any use, transfer or exchange, For Value or otherwise, of a Licensed Product. Sales include all Sales by the Licensee, its Affiliates and its Sublicensees and includes any transfer by the
Licensee to an Affiliate or sublicensee where there is no subsequent Sale (i.e., the Licensed Product is not further resold or transferred). For the avoidance of doubt, Sales shall not be deemed to include (a) any transfer by the
Licensee or a Sublicensee to an Affiliate or Sublicensee, where there is a 

  
 3 of 27 

 Confidential Treatment Requested 

 

	 	
subsequent Sale of the Licensed Product; only the subsequent Sale is used to calculate any amount due, (b) the use, performance or provision of a Licensed Product for research and
development purposes, clinical or otherwise, or (c) reasonable distributions as samples or given as donations for indigent use. 

  

	1.27	“Sublicensee” means a Person to whom the Licensee has granted a sublicense pursuant to Section 2.5 of this Agreement. 

 

	1.28	“Term” is defined in Section 9.1. 

  

	1.29	“Third Party” means any Person other than the Parties and their Affiliates. 

  

	1.30	“United States” means the United States of America. 

  

	1.31	“United States Government” means the Federal Government of the United States. 

  

	1.32	“Valid Patent Claim” means (i) a pending patent claim included within the Licensed Patents or (ii) an issued and unexpired patent claim included within the Licensed Patents which has not been held
permanently revoked, unenforceable or invalid by a decision of a court or other governmental agency of competent jurisdiction, to which an appeal has not or cannot be taken within the time allowed for appeal, and which has not been disclaimed,
denied or admitted to be invalid or unenforceable through reissue, disclaimer or otherwise. 

 ARTICLE 2 

GRANT OF LICENSE 

2.1 Grant of License. Subject to the terms and upon the conditions set forth in this Agreement, UABRF hereby grants to the Licensee an exclusive right
and license to (a) practice the Licensed Patents and (b) make, have made, develop, use, lease, offer to sell, sell, import and export Licensed Products, within the Licensed Field of Use in the Licensed Territory during the Term. Subject to
the prior written consent of UABRF, which consent shall not be unreasonably withheld, the Licensee may transfer its rights under this Agreement to an Affiliate, provided such Affiliate assumes all of the obligations of the Licensee under this
Agreement. 
 2.2 Rights of the United States Government. It is understood that if a United States Governmental Authority has funded research, during
the course of or under which any of the Licensed Patents were conceived or made, the United States Government is entitled, as a right, under the provisions of 35 U.S.C. §§ 200-212 and applicable regulations of Chapter 37 of the Code of
Federal Regulations, to a non-exclusive, non-transferable, paid-up license to practice or have practiced and use the affected Licensed Patents for governmental purposes. The Licensee acknowledges that the rights and license granted to it pursuant to
this Agreement are subject to any and all rights of the United States Government. 
 2.3 Reservation of Rights by UABRF and its Affiliates. UABRF
reserves the right, for itself and for its Affiliates, to: 
  

	 	(a)	practice and use, and to permit its Representatives to practice and use, the Licensed Patents within the Licensed Field of Use for Non-Commercial Research Purposes; 

  
 4 of 27 

 Confidential Treatment Requested 

 

	 	(b)	grant to non-profit academic, educational or research institutions and Governmental Authorities, non-exclusive, royalty-free licenses to make and use the Licensed Patents within the Licensed Field of Use for
Non-Commercial Research Purposes; 

  

	 	(c)	permit their respective Representatives to disseminate and publish scientific findings from research related to the Licensed Patents subject to Section 8.2. 

 

	 	(d)	practice, use and otherwise commercialize, including licensing, the Licensed Patents to Third Parties for applications and uses outside of the Licensed Field of Use. 

2.4 Title Remains with UABRF. All right, title and interest in and to the Licensed Patents remain with UABRF. Except as provided in this Agreement, no
express or implied licenses with respect to the Licensed Patents or any other rights are transferred or granted to the Licensee by implication, estoppel or otherwise. 

2.5 Right to Grant Sublicenses. The Licensee has the right to grant sublicenses to any Person under this Agreement on the following terms and
conditions: 
  

	 	(a)	the execution of a sublicense shall not in any way diminish, reduce or eliminate any of the Licensee’s obligations under this Agreement, and the Licensee shall remain primarily liable for such obligations and any
breach of any provision of this Agreement by a Sublicensee; 

  

	 	(b)	any sublicense so granted is limited to the Licensed Field of Use; 

  

	 	(c)	any sublicense so granted shall be subject and subordinate to, and consistent with, the terms of this Agreement; 

  

	 	(d)	the Licensee may not sublicense the right to prosecute or protect the Licensed Patents to a Sublicensee, without obtaining the prior written consent of UABRF; 

 

	 	(e)	any sublicense shall also provide that, in the event this Agreement is terminated or upon the expiration of the Term, such sublicenses shall automatically become a direct license with UABRF on the terms stated therein;

  

	 	(f)	all sublicenses are to be For Value and the Licensee shall not receive from a Sublicensee anything of value in lieu of cash payments in consideration for any sublicense under this Agreement without the prior written
consent of UABRF; 

  

	 	(g)	the Licensee shall provide UABRF with a copy of any such sublicense granted by it under this Agreement within thirty (30) days of the execution of the sublicense; 

  
 5 of 27 

 Confidential Treatment Requested 

 

	 	(h)	all such copies of sublicense agreements may be redacted to exclude confidential scientific information and other information required by the Sublicensee to be kept confidential, provided that all relevant financial
terms and information shall be retained and shall not be redacted; the disclosure of sublicense agreements to UABRF shall be subject to the confidentiality obligations set forth in this Agreement; and 

 

	 	(i)	UABRF is a third party beneficiary to each sublicense and each agreement evidencing a sublicensing arrangement shall include a statement and an acknowledgement by the Sublicensee to this effect. 

ARTICLE 3 

DEVELOPMENT AND COMMERCIALIZATION 

3.1 Development and Commercialization Plan. During the Term, the Licensee shall use good faith, reasonable commercial efforts to develop, manufacture,
commercialize and market the Licensed Patents through a diligent program designed to accomplish the commercial exploitation of the same and to make the technology covered by or embedded in the Licensed Patents available to the general public in
accordance with the procedures and practices that are usual and customary for similar technologies and industries. The Parties acknowledge that the Licensee has provided to UABRF the Development and Commercialization Plan set forth on attached
Exhibit B which sets forth its current development and commercialization objectives. The Parties further acknowledge and agree that the Development and Commercialization Plan is, and the development and commercialization milestones set forth therein
are, reasonable. 
 3.2 Amendment of Development and Commercialization Plan and Milestones. All variations and deviations from and changes to the
Development and Commercialization Plan and milestones must be expressly approved in writing by UABRF, such consent not to be unreasonably withheld. 
 3.3
Development and Commercialization Report. The Licensee shall provide UABRF, on each July 1 and January 1 for a period of six (6) years from the Effective Date or until the First Commercial Sale, with written progress reports
detailing the activities of the Licensee relating to the Development and Commercialization Plan. As a general guide, each such report shall provide information regarding the accomplishments and progress made by the Licensee during the prior
reporting period and the objectives and goals to be reached during the forthcoming reporting period. The Licensee will thereafter provide such reports to UABRF on an annual basis on the anniversary of the Effective Date. 

3.4 Regulatory Approvals. With respect to each Licensed Product, and to the extent regulatory approval is required, the Licensee shall use commercially
reasonable efforts to obtain the approval of each applicable Regulatory Authority prior to the First Commercial Sale in each country/jurisdiction in which the Licensee intends to sell Licensed Products. 

3.5 Patent Markings. The Licensee shall ensure that each Licensed Product manufactured and/or sold in the United States shall bear patent markings that
meet all applicable requirements of 35 U.S.C. §287, as amended from time to time. All Licensed Products manufactured and/or sold outside of the United States shall be marked in such a manner as to conform to the Applicable Law of such
country/jurisdiction. 
 3.6 Manufacturing in the United States. The Licensee shall use commercially reasonable efforts to substantially manufacture
in the United States any Licensed Products sold in the United States that incorporate any invention or intellectual property owned by UABRF and are licensed to the Licensee under this Agreement that was developed using funds provided by a United
States Governmental Authority, as identified on Exhibit A. 

  
 6 of 27 

 Confidential Treatment Requested 

 

 ARTICLE 4 

PROTECTION OF THE LICENSED PATENTS; PATENT
PROSECUTION 
 4.1 Future Protection Activities. 
  

	 	(a)	UABRF Retains Primary Responsibility. Subject to the terms and conditions set forth in this Agreement, UABRF shall, from the Effective Date, continue to be primarily responsible for undertaking all
Protection Activities relating to the Licensed Patents. UABRF shall, subject to consultation with the Licensee select such legal counsel as it in its sole discretion deems appropriate to assist it in this process. 

 

	 	(b)	Co-operation of the Licensee. The Licensee shall cooperate with UABRF and its designated legal counsel in connection with the Protection Activities. 

 

	 	(c)	Consultation with the Licensee. UABRF shall, and shall cause its designated legal counsel to, consult with the Licensee in connection with such Protection Activities and the Licensee shall be given
reasonable opportunity to discuss, advise and review issues with UABRF and its designated legal counsel in connection therewith. 

  

	 	(d)	Foreign Protection Requested by the Licensee. The Licensee must notify UABRF in writing identifying in which foreign countries and jurisdictions, if any, the Licensee wishes to undertake Protection
Activities with respect to any Licensed Patents. Exhibit A shall be amended accordingly to reflect these designations. 

  

	 	(e)	Foreign Patent Protection Not Requested by the Licensee. UABRF may elect to undertake Protection Activities with respect to any Licensed Patents in any country or jurisdiction not so designated by the
Licensee pursuant to Section 4.1(d) above. In such cases (i) UABRF shall be responsible for all Protection Expenses incurred in connection therewith and the Licensee shall not be responsible for such expenses and (ii) the Licensed
Patents so affected shall no longer be deemed to be licensed to the Licensee in such country or jurisdiction and shall be deemed to have been disclaimed by the Licensee (each, a “Disclaimed Licensed Patent”), (iii) the Licensee shall
forfeit and shall no longer have any rights or obligations with respect thereto in such country or jurisdiction and (iv) Exhibit A shall be amended accordingly to delete the affected Licensed Patents for such country or jurisdiction.

  
 7 of 27 

 Confidential Treatment Requested 

 

	 	(f)	Disclaimed Licensed Patents. The Licensee may, at any time during the Term, provide at least sixty (60) days written notice to UABRF that it no longer wishes to be responsible for the Protection
Expenses in connection with one or more Licensed Patents. In such cases, (i) the Licensee shall continue to be responsible for all Protection Expenses incurred in connection therewith until the expiration of such sixty (60) day notice
period and thereafter shall not be responsible for such expenses and (ii) the Licensed Patent(s) so affected shall no longer be deemed to be licensed to the Licensee and shall be deemed to have been disclaimed by the Licensee (each, a
“Disclaimed Licensed Patent”), (iii) the Licensee shall forfeit and shall no longer have any rights or obligations with respect thereto and (iv) Exhibit A shall be amended accordingly to delete the affected Licensed Patent(s).

 4.2 Information to the Licensee. UABRF shall provide the Licensee with copies of all issued patents relating to the Licensed
Patents. UABRF shall provide copies of all patent applications and all filings, correspondence and other related documentation pertaining to prosecutorial matters arising from the Protection Activities, including, but not limited to, all office
actions, requests for examinations and restriction requirements. 
 ARTICLE 5 

FINANCIAL TERMS 

5.1 Accrued Licensing Obligations. Under that certain Exclusive License Agreement made between the Parties on March 1, 1998 (the “Original
License”) financial obligations including Protection Expenses and other payments due as consideration for grant of the Original License were made and agreed upon which were not met per the terms of the Original License. Subsequently, a
Convertible Promissory Note in the principal amount of Seventy-Five Thousand and No/100 Dollars ($75,000.00) was executed on June 9, 2010 (The “2010 Note”) to evidence such expenses (the “Disputed IP Expenses”) between the
Parties. The Parties acknowledge and agree that as of the date of this Agreement the outstanding principal and accrued interest on the 2010 Note totals One Hundred One Thousand, Nine Hundred and Ninety Five Dollars ($101,995.00). The Parties also
agree that as of the date hereof, Minimum Annual Royalties due to be paid by the Licensee under the Original License for the years 2009 through 2013 total One Hundred Sixty Thousand Dollars ($160,000.00) and that as of the Effective Date of this
Agreement they remain unpaid The Licensee has indicated that it can pay only Ten Thousand and No/100 Dollars as Minimum Annual Royalties due for each of those years and UABRF has agreed to accept such amount and to waive the remaining One Hundred
and Twenty Thousand and No/100 Dollars ($120,000.00). Accordingly, as of the Effective Date of this Agreement, the Licensee owes UABRF One Hundred Forty One Thousand Nine Hundred and Ninety Five and No/100 Dollars ($141,995.00) which it agrees to
repay by no later than August 31, 2015. Contemporaneously with the execution of this Agreement, Vaxin is executing a separate, promissory note for One Hundred Forty One Thousand Nine Hundred and Ninety Five and No/100 Dollars ($141,995.00) to
evidence its obligation to repay such amount. 
 5.2 Future Protection Expenses. During the Term and with respect to each Licensed Patent, other than
Disclaimed Licensed Patents, the Licensee will be financially responsible for the payment of all Protection Expenses incurred after the January 1, 2010. The Licensee shall pay 

  
 8 of 27 

 Confidential Treatment Requested 

 

 
such amounts to UABRF within thirty (30) days of receipt of an invoice for the same from UABRF. UABRF shall be responsible for all Protection Expenses incurred in connection with each
Disclaimed Licensed Patent in countries/jurisdictions not designated by the Licensee pursuant to Section 4.1(d) above. 
 5.3 License Fee. No
license issue fee is required based on prior consideration under the Original Agreement. 
 5.4 Issuance of Stock in the Licensee to UABRF. Seven
hundred-fifty thousand (750,000) shares of the Licensee’s common stock, par value $0.01 per share, were issued to UABRF in connection with the execution of the Original License. An additional Two Hundred Two Thousand, Two Hundred and
Eighty-Four (202,284) shares of Licensee’s common stock, par value $0.01 per share were issued to UABRF in 2010 in relation to the conversion of a prior promissory note between the Parties, originally due December 15, 2009. 

5.5 License Maintenance Fees. The Licensee shall pay UABRF for each calendar year an amount of Twenty Thousand and No/100 dollars ($20,000), such
payment being due within thirty (30) days after the end of each calendar year beginning 2014, unless the Licensee has given notice of termination to UABRF prior to such due date. 

5.6 Running Royalty Payments. During the Term and with respect to each country or jurisdiction within the Licensed Territory, the Licensee shall pay to
UABRF a continuing royalty of [****] percent ([****]%) on all Net Sales arising in such country/jurisdiction until the expiration of the last Valid Patent Claim in that country/jurisdiction. All amounts owing to UABRF under this Section shall be
paid on a quarterly basis, on or before the thirtieth (30th) day following the end of the calendar quarter in which such amounts were earned. 

5.7 Minimum Royalty Payments. Beginning upon the First Commercial Sale, the Licensee shall be obligated to pay minimum annual royalty payments to
UABRF. In the event that the aggregate running royalty payments paid by the Licensee to UABRF pursuant to Section 5.6 above do not reach the minimum payment obligations set forth below by the date set forth below, then the Licensee shall,
within thirty (30) days following the end of the calendar year, pay UABRF the difference between such aggregate royalty payment actually paid to UABRF and the minimum payment set forth below. All such minimum annual royalty payments shall be
nonrefundable. 
  

					
	 Period
	  	Minimum Royalty Payment	 
	 First Calendar Year Following First Commercial Sale
	  	$	[****	] 
	 Second Calendar Year Following First Commercial Sale
	  	$	[****	] 
	 Third Calendar Year Following First Commercial Sale
	  	$	[****	] 
	 Each Calendar Year Thereafter
	  	$	[****	] 

  
 **** Confidential treatment
requested 

  
 9 of 27 

 Confidential Treatment Requested 

 

 5.8 Royalty Reports. At the time of payment of Running Royalties due per 5.6 above, Licensee shall
provide to UABRF a written report setting forth all applicable information specified in Exhibit C, which such report shall accompany the payment of all running royalties due to be paid to UABRF by the Licensee with respect to the preceding calendar
quarter. Reports furnished must include the calculation of running royalties by Licensed Product and by country/jurisdiction and must include the rate of currency conversion and the date such conversion was calculated as described in
Section 5.13 of this Agreement, all in substantially the format set forth in Exhibit E. If the Licensee is required to pay an annual minimum royalty payment, at the time such payment is made, the Licensee shall also furnish a written report
providing, to the extent not already provided to UABRF, all of the information required to be set forth in the quarterly reports discussed above and the additional amount being paid by the Licensee which accompanies the report, being the difference
between aggregate running royalty payment actually paid to UABRF in that calendar year and the minimum payment required to be paid. 
 5.9 Non-Royalty
Income. The Licensee shall not receive any Non-Royalty Income, in connection with its exercise of the rights granted to it pursuant to this Agreement. 

5.10 Royalty Payments from Sublicensees. The Licensee shall pay to UABRF an amount equal to that which the Licensee would have been required to pay to
UABRF had the Licensee affected the Sales actually affected by the Sublicensee. 
 5.11 Address for Payments. Except as otherwise directed by UABRF,
all amounts due to be paid by the Licensee to UABRF pursuant to this Agreement shall be paid to UABRF at the address set forth below its signature on the signature page of this Agreement. 

5.12 Late Payment Penalty. The balance of any amount which remains unpaid more than thirty (30) days after it is due to UABRF shall accrue
interest until paid at the rate equal to the lesser of [****] percent ([****]%) per calendar month or the maximum amount allowed under Applicable Law. However, in no event shall this interest provision be construed as a grant of permission for
payment delays. 
 5.13 Currency Conversion. All amounts due to be paid to UABRF pursuant to this Agreement shall be made in United States dollars.
Any and all amounts received by the Licensee or generated in foreign currency shall be converted into United States dollars at the official rate of exchange from such currency to United States dollars at the rate quoted in the Wall Street Journal
(United States edition) for the last business day of the calendar quarter in which running royalties are due and payable to UABRF or on a business day no earlier than five (5) business days before payment is made to UABRF. 

5.14 Foreign Taxes. Any tax required to be withheld by the Licensee under the laws of any foreign country or jurisdiction for the account of UABRF
shall be promptly paid by the Licensee for and on behalf of UABRF to the appropriate Governmental Authority, and the Licensee shall use reasonable commercial efforts to furnish UABRF with proof of payment of such tax, together with official or other
appropriate evidence issued by the applicable Governmental Authority. Any such amounts actually paid on UABRF’s behalf shall be deducted from any amounts due to be paid to UABRF under this Agreement. 

 
 **** Confidential treatment requested 

  
 10 of 27 

 Confidential Treatment Requested 

 

 ARTICLE 6 

RECORDKEEPING AND AUDIT RIGHTS 

6.1 Books and Records. The Licensee shall keep complete and accurate books, accounts and other records and documentation necessary to ascertain all
transactions and events pursuant to which payments due to UABRF pursuant to this Agreement arise and are accrued and to verify the accuracy and completeness of such amounts. All such books, accounts and other records and documentation shall be kept
at the Licensee’s principal place of business for a period of not less than six (6) years following the end of the calendar year to which they pertain. 

6.2 Right to Audit. During the Term and for a period of one (1) year thereafter, UABRF shall have the right to have the Licensee’s books and
records audited by a qualified, independent accounting firm of its choosing, under appropriate confidentiality provisions such as those set forth in Section 8.4 of this Agreement, to ascertain the accuracy of the reports and payments due to
UABRF under this Agreement and compliance by the Licensee, its Affiliates and its Sublicensees with their obligations pursuant to this Agreement and any sublicense. Such audit shall be conducted on ten (10) days advance notice during normal
business hours and in a manner that does not interfere unreasonably with the Licensee’s business but not more than once in any twelve (12) month period. If any such examination reveals that the Licensee has underpaid or underreported any
amount due under this Agreement to UABRF for any calendar quarter examined, the Licensee shall promptly pay to UABRF the amount so underpaid or underreported. 

6.3 Reimbursement of Cost of Audit. If any such examination reveals that the Licensee has underpaid or underreported any amount due under this
Agreement to UABRF by more than five percent (5%) for any calendar quarter examined, the Licensee shall promptly reimburse UABRF the full reasonable costs and expenses incurred by it with respect to the audit. 

ARTICLE 7 

INFRINGEMENT; ENFORCEMENT 

7.1 Notification of Infringement. During the Term, each Party shall provide prompt written notice to the other Party of any actual infringement or
suspected/potential infringement of the Licensed Patents of which such Party is or becomes aware and shall provide, to the extent reasonable and practicable, any available evidence of such infringement by a Third Party (an “Infringement
Notice”). 
 7.2 Licensee Right to Pursue/Prosecute. During the Term, the Licensee shall have the right to resolve, in the Licensed Field of Use
and in the Licensed Territory, any suspected/potential infringement and prosecute any infringement of any Licensed Patents, in its own name and at its own expense, provided: 
  

	 	(a)	the affected Licensed Patent remains exclusively licensed to the Licensee and is not a Disclaimed Licensed Patent; 

  

	 	(b)	the claim relates to a Valid Patent Claim; and 

  

	 	(c)	the Licensee remains in compliance, in all material respects, with its obligations under this Agreement. 

  
 11 of 27 

 Confidential Treatment Requested 

 

 The Licensee shall use commercially reasonable efforts to abate or terminate such infringement without
resorting to litigation, which may include negotiating and executing a sublicense agreement which complies with the terms of Section 2.5 of this Agreement. Before the Licensee commences an action with respect to any infringement or potential
infringement, it agrees to consider the views of UABRF and the potential effects on the public interest in making its decision whether or not to sue. UABRF agrees to cooperate with the Licensee in connection with any remedial action undertaken by
the Licensee and shall be responsible for the costs and expenses incurred by it and for those costs and expenses incurred by it at the reasonable request of the Licensee with respect to such cooperation. 

7.3 Control of Suit; Joinder; Expenses. 
  

	 	(a)	Initiated by the Licensee. If the Licensee wishes to commence a lawsuit, it must do so within ninety (90) days following the date of the relevant Infringement Notice, and it shall bear all costs and
expenses incurred by it in connection with such lawsuit. UABRF agrees to cooperate fully with the Licensee in connection with such lawsuit and shall be responsible for the costs and expenses incurred by it and for those costs and expenses incurred
by it at the reasonable request of the Licensee with respect to such cooperation. 

  

	 	(b)	Initiated by UABRF. If the Licensee elects not to exercise its right to commence, or fails to commence, an action within ninety (90) days of the date of the relevant Infringement Notice, UABRF may do
so at its own expense, and shall retain sole control over the direction of such lawsuit. The Licensee agrees to cooperate fully with UABRF in connection with such lawsuit and shall be responsible for the costs and expenses incurred by it with
respect to such cooperation. If UABRF files an infringement lawsuit, the Licensee may not thereafter commence a lawsuit against the same infringing party with respect to the same acts of infringement which are the subject of UABRF’s lawsuit or
with respect to which settlement is reached by the infringing party and UABRF. 

  

	 	(c)	Joinder by UABRF. UABRF, to the extent permitted by Applicable Law, may elect to join in as a party to any infringement lawsuit initiated by the Licensee, in which case, both Parties shall jointly control
the lawsuit and shall equally share the responsibility of all legal fees, costs and expenses, unless otherwise agreed to by the Parties. The Licensee may not join UABRF in as a party to any lawsuit initiated by it without the prior written consent
of UABRF, and without prior written agreement between the Parties as to the responsibility between the Parties for all costs and expenses incurred by the Parties. If UABRF is involuntarily joined as a party to a lawsuit initiated by the Licensee,
the Licensee shall pay all legal fees, costs and expenses incurred by UABRF arising out of such joinder and participation, including, but not limited to legal fees, costs and expenses reasonably incurred by legal counsel selected and retained by
UABRF to represent it in such lawsuit. While UABRF remains a party to any infringement 

  
 12 of 27 

 Confidential Treatment Requested 

 

	 	
lawsuit initiated by the Licensee, UABRF may not thereafter commence a lawsuit against the same infringing party with respect to the same acts of infringement which are the subject of the
Licensee’s lawsuit or with respect to which settlement is reached by the infringing party, the Licensee and UABRF. 

 7.4
Settlement. The Licensee may not settle, enter into a consent judgment or other voluntary final disposition of any lawsuit initiated by it or to which it is a party without the prior written consent of UABRF, which consent shall not be
unreasonably withheld. Neither Party may settle or otherwise dispose of any lawsuit to which it is a party, which admits liability on the part of the other Party or which requires the other Party to pay money damages nor issue a formal statement
without such other Party’s prior written consent in each case. 
 7.5 Recoveries. 

 

	 	(a)	Lawsuit initiated by the Licensee and in which only the Licensee is a party. With respect to any lawsuit commenced by the Licensee pursuant to Section 7.3(a) above and in which UABRF is not a party,
any recovery of damages shall first be applied in satisfaction of the costs and expenses incurred by the Licensee in bringing such lawsuit, including attorneys’ fees, provided they are reasonably incurred, and any balance shall be treated in
accordance with Section 5.7 of this Agreement. 

  

	 	(b)	Lawsuit initiated by the Licensee and in which UABRF joins. 

  

	 	(i)	With respect to any lawsuit commenced by the Licensee pursuant to Section 7.3(a) above and in which UABRF is involuntarily joined as a party, any recovery of damages shall first be applied in satisfaction of the
costs and expenses incurred by the Licensee and UABRF in bringing such lawsuit, including attorneys’ fees, provided they are reasonably incurred (which such costs and expenses shall include all costs and expenses incurred by UABRF resulting
from such joinder and participation, including, but not limited to legal fees and expenses reasonably incurred by legal counsel selected and retained by UABRF to represent it in such lawsuit), and any balance shall be treated in accordance with
Section 5.7 of this Agreement. 

  

	 	(ii)	With respect to any lawsuit commenced by the Licensee pursuant to Section 7.3(a) above and in which UABRF voluntarily joins as a party, any recovery of damages (whether compensatory or punitive in nature) shall
first be applied, pro rata, in satisfaction of the costs and expenses incurred by the Parties in bringing such lawsuit, including attorneys’ fees, provided they are reasonably incurred, and any balance shall be treated in accordance with
Section 5.7 of this Agreement. 

  

	 	(c)	Lawsuit initiated by UABRF. With respect to any lawsuit commenced by UABRF pursuant to Section 7.3(b) above, [****]. 

7.6 Inapplicability of Licensee’s Rights. Notwithstanding Sections 7.1 – 7.5 above, the rights and obligations of the Licensee under this
article shall not apply to (a) any Licensed Patents in which there are no Valid Patent Claims remaining or (b) any Disclaimed Licensed Patent. 
  

**** Confidential treatment requested 

  
 13 of 27 

 Confidential Treatment Requested 

 

 ARTICLE 8 

OTHER COVENANTS AND AGREEMENTS 

8.1 Use of Names. No Party may, without the prior written consent of the other Party: 

 

	 	(i)	use (a) the name of the other Party or its Affiliates, if applicable, (b) the name or image of any Representative of the other Party, or (c) any trade-name, trademark, trade device, service mark, symbol,
image, icon, abbreviation, contraction or simulation thereof owned by the other Party in any publication, advertising or sales promotional material, press release or in any marketing or advertising documentation or material; or 

 

	 	(ii)	represent, either directly or indirectly, that any product or service of the other Party is a product or service of the representing Party or that it is made in accordance with or utilizes the information or documents
of the other Party. 

 Notwithstanding the above, the Licensee may disclose that it has received a license from UABRF in connection with any
Licensed Product, and either Party may use the name of the other Party to the extent such use is reasonably necessary for complying with Applicable Law. 

8.2 Publications. In furtherance of the rights reserved in Section 2.3(c) of this Agreement, UABRF or its Affiliates shall submit the proposed
publication or disclosure to the Licensee at least thirty (30) days prior to submission for publication or disclosure to allow the Licensee to review the matter for disclosure of Proprietary Information of the Licensee. The Licensee shall have
thirty (30) days from its receipt of such proposed publication or disclosure to review and to provide written notice to UABRF or its Affiliate who provided the submission requiring removal of the Licensee’s Proprietary Information. If the
Licensee does not provide written notice of such request to UABRF or its Affiliate who provided the submission within thirty (30) days after receipt of the proposed publication or disclosure from UABRF or its Affiliate, UABRF or its Affiliate
shall be free to publish or disclose to third parties the proposed publication or disclosure without further obligation to the Licensee. 
 8.3 Insurance
Coverage. Prior to commencing any human clinical trial, and during the Term, the Licensee shall cause to be in effect through purchase from a reputable insurance company or, upon the consent of UABRF, through a self-insurance program, at its
sole expense, and shall maintain “occurrence based type” liability insurance coverage or, if the Licensee is unable to obtain “occurrence based type” liability insurance, a “claims made type” liability insurance
coverage (with at least ten (10) years tail coverage). Such insurance coverage shall include a contractual endorsement providing coverage for liability which may be incurred in connection with this Agreement, including, but not limited to
general liability and products liability, and such other type of insurance coverage required by Applicable Law or which Licensee deems necessary to enable the Licensee to perform its obligations under this Agreement. All such insurance coverage
shall list UABRF and its Affiliates as additional insureds. The Licensee shall 

  
 14 of 27 

 Confidential Treatment Requested 

 

 
provide evidence of such insurance coverage to UABRF within ten (10) business days of the Effective Date of this Agreement and at least annually thereafter. All such insurance coverage shall
require the insurance provider, or in the case of a self -insurance program, the Licensee, to provide UABRF with at least thirty (30) days prior written notice of any change in the terms or cancellation of coverage. 

8.4 Confidentiality. 
  

	 	(a)	Exchange of Proprietary Information. The Parties acknowledge that during the Term they are likely to share information with each other that they each consider to be confidential and proprietary
(“Proprietary Information”). For the purposes of this Agreement, the Party that discloses Proprietary Information shall be referred to as the “Disclosing Party” and the Party receiving the Proprietary Information, the Receiving
Party. 

  

	 	(b)	Nature of Proprietary Information. The Parties agree that all information that is provided to the other Party shall be deemed to be Proprietary Information. Notwithstanding the above, the Parties
specifically agree that any reports provided by the Licensee pursuant to this Agreement shall be considered Proprietary Information. 

  

	 	(c)	Restrictions. With respect to all Proprietary Information disclosed to it, the Receiving Party (i) shall keep it confidential (other than as permitted by this Agreement), (ii) shall store and
maintain it with the same diligence and care as its own proprietary information, but no less than reasonable diligence and care, (iii) may only use it for the purpose for which it was disclosed by the Disclosing Party, (iv) may not
disclose it (other than as permitted by this Agreement), (v) may not deconstruct, modify or copy it (other than as permitted by this Agreement), and (vi) may not transfer or assign it to any Third Party without the prior written consent of
the Disclosing Party. 

  

	 	(d)	Access to the Proprietary Information. The Proprietary Information may be used by, and disclosed to, on an “as-needed” basis, the Receiving Party’s Representatives. The Licensee may disclose
Proprietary Information relating to the UABRF intellectual property rights to investors, prospective investors, consultants, collaborators and other Third Parties in the chain of manufacturing and distribution, if and only if, the Licensee obtains
from such recipient a written confidentiality agreement, the provisions of which are at least as protective of UABRF’s Proprietary Information as these set forth in this Section 8.4. Prior to disclosing Licensee’s Proprietary
Information to any Third Party for any purpose, including Non-Commercial Research Purposes, UABRF shall obtain Licensee’s written consent and obtain from such recipient a written confidentiality agreement, the provisions of which are at least
as protective of Licensee’s Proprietary Information as these set forth in this Section 8.4. Each Party will promptly notify the other Party of any unauthorized use of or access to the Proprietary Information of which it becomes aware.

  
 15 of 27 

 Confidential Treatment Requested 

 

	 	(e)	Exceptions to Confidentiality Obligation. The restrictions of confidentiality described above shall not apply to Proprietary Information (i) which as of the Effective Date or subsequent thereto is or
becomes available to the public without breach of this Agreement, (ii) if it is lawfully obtained from a Third Party not bound by similar confidentiality and use restrictions and obligations, (iii) if it is known by the Receiving Party
prior to disclosure as evidenced by contemporaneous records, or (iv) if it is at any time developed by the Receiving Party independently of and without reference to any disclosure made pursuant to this Agreement. In addition, the
confidentiality obligations shall not apply to the Receiving Party if the Receiving Party is legally required by applicable law, court order or Governmental Authority to disclose the Proprietary Information, provided the Receiving Party discloses
only the minimum to comply and, if possible and in light of the circumstances, provides reasonable prior notice to the Disclosing Party to enable it to contest the requirement or to seek a protective order. 

 

	 	(f)	Termination or Expiration of this Agreement. Upon the expiration of the Term, or the earlier termination of this Agreement, each Receiving Party shall, at the Disclosing Party’s option and upon
written notice thereof to the Receiving Party, return all Proprietary Information, copies and other tangible expressions thereof, to the Disclosing Party or provide the Disclosing Party with written notice that the Proprietary Information in its
possession, or in the possession of its Representatives, has been destroyed within thirty (30) days after receipt of the Disclosing Party’s written notice to the Receiving Party requiring the Receiving Party to destroy the Proprietary
Information in its possession. The Receiving Party may retain one archival copy of the Proprietary Information for purposes of compliance with its obligations under this Agreement. 

 

	 	(g)	Continuing Obligations after Termination/Expiration. The restrictions and obligations set forth in Section 8.4(c) above shall continue for five (5) years from the termination or expiration of
this Agreement, or with respect to information identified by Disclosing Party as trade secrets at the time of disclosure for so long as such information shall remain a trade secret under Applicable Law. 

ARTICLE 9 

TERM AND TERMINATION 

9.1 Term. This Agreement shall commence on the Effective Date and shall continue until the date of expiration of the last to expire of any Valid Patent
Claim (inclusive of any extensions, supplementary protection certificates or their equivalents) within the Licensed Patents, unless terminated sooner in accordance with the terms of this Agreement (the “Term”). 

9.2 Termination by the Licensee. The Licensee may terminate this Agreement at any time, in its sole discretion, by giving not less than ninety
(90) days prior written notice to UABRF. Upon the reasonable request of UABRF, the Licensee shall provide assistance, at UABRF’s expense, to UABRF to enable UABRF to facilitate and effect the transfer of applicable information and
documents regarding the Licensed Patents to a new licensee. 

  
 16 of 27 

 Confidential Treatment Requested 

 

 9.3 Termination by UABRF. UABRF shall have the right to immediately terminate this Agreement upon the
occurrence of any one or more of the following events: 
  

	 	(a)	if the Licensee is in material default of any provision of this Agreement or its obligations under this Agreement and such default has not been remedied within thirty (30) days or such longer cure period specified
in the notice after receipt of a notice to cure from UABRF; 

  

	 	(b)	upon the occurrence of the third separate default by the Licensee within any consecutive three (3) year period for failure to make payments when due under this Agreement; 

 

	 	(c)	if the Licensee fails to meet any of the development and commercialization milestones set forth in the Development and Commercialization Plan; 

 

	 	(d)	if by the end of the third (3rd) calendar year after the First Commercial Sale occurred, or by January 1, 2015, whichever comes first, fifty percent
(50%) of the minimum royalty payment described in Section 5.8 of this Agreement due in that calendar year is not originating from Net Sales; 

  

	 	(e)	if an examination by UABRF pursuant to Section 6.2 shows an underreporting or underpayment by the Licensee in excess of ten percent (10%) of any amounts due to UABRF under this Agreement in any twelve
(12) month period; 

  

	 	(f)	if the Licensee is convicted of a felony (or similar crime in a jurisdiction outside of the United States) relating to the manufacture, use or sale of a Licensed Product; 

 

	 	(g)	if the Licensee shall become insolvent, shall make an assignment for the benefit of its creditors, or shall have a petition in bankruptcy filed for or against it; or 

 

	 	(h)	if the Licensee disclaims payment of all Protection Expenses. 

 9.4 Effect of Termination or Expiration.
Any termination or expiration of this Agreement will not relieve either Party of any obligation or liability accrued prior to such termination or expiration. 

ARTICLE 10 

COVENANTS; REPRESENTATIONS AND WARRANTIES; LIMITATIONS
ON UABRF’S OBLIGATIONS 
 10.1 The Licensee. The Licensee makes the following representations
and warranties to UABRF. 
  

	 	(a)	The Licensee is a corporation, duly incorporated, validly existing and in good standing under the laws of the State of Delaware. 

  
 17 of 27 

 Confidential Treatment Requested 

 

	 	(b)	The Licensee has all necessary corporate power and authority to enter into this Agreement and to consummate the transactions contemplated hereby. 

 

	 	(c)	The execution, delivery and performance of this Agreement by the Licensee will not conflict with or result in a breach of, or entitle any party thereto to terminate, an agreement or instrument to which the Licensee is a
party, or by which any of the Licensee’s assets or properties are bound. 

  

	 	(d)	This Agreement has been duly authorized, executed and delivered by the Licensee and constitutes a legal, valid and binding agreement of the Licensee, enforceable against the Licensee in accordance with its terms, except
as such enforceability may be limited by bankruptcy, insolvency, moratorium, reorganization or other similar laws affecting creditors’ rights generally. 

  

	 	(e)	Any activity undertaken with the Licensed Patents and the Licensed Products will be conducted in compliance with all Applicable Laws. 

10.2 UABRF. UABRF makes the following representations and warranties to the Licensee. 

 

	 	(a)	UABRF is a non-profit corporation, duly incorporated, validly existing and in good standing under the laws of the State of Alabama. 

  

	 	(b)	UABRF has all necessary corporate power and authority to enter into this Agreement and to consummate the transactions contemplated hereby. 

 

	 	(c)	The execution, delivery and performance of this Agreement by UABRF does not conflict with or contravene its governing documentation, nor will the execution, delivery and performance of this Agreement by UABRF conflict
with or result in a breach of, or entitle any party thereto to terminate, an agreement or instrument to which UABRF is a party, or by which any of UABRF’s assets or properties are bound. 

 

	 	(d)	This Agreement has been duly authorized, executed and delivered by UABRF and constitutes a legal, valid and binding agreement of UABRF, enforceable against UABRF in accordance with its terms, except as such
enforceability may be limited by bankruptcy, insolvency, moratorium, reorganization or other similar laws affecting creditors’ rights generally. 

  

	 	(e)	UABRF has the right to grant the license under this Agreement. 

  

	 	(f)	To UABRF’s best knowledge and based upon information and representations and warranties made to it by the Inventor, UABRF owns all right, title and interest in the Licensed Patents and there have been no claims
made against UABRF asserting the invalidity or non-enforceability of, or with respect to the Licensed Patents, and UABRF is not aware that any such claims exist. 

  

	 	(g)	During the Term, UABRF will not undertake any Management Activities with respect to the Licensed Patents unless it is a Disclaimed Licensed Patent. 

 

	 	(h)	The performance of Management Activities with respect to a Disclaimed Licensed Patent will not conflict with or result in a breach of any of the terms, conditions, or provisions of, or constitute a default under, this
Agreement, and will not give rise to a cause of action by a Third Party against the Licensee, with respect to the remaining Licensed Patents licensed to the Licensee pursuant to this Agreement. 

  
 18 of 27 

 Confidential Treatment Requested 

 

 10.3 Limitations on UABRF’s Representations and Warranties. Except as set forth in this
Agreement, UABRF makes no other representations or warranties of any kind. In particular, UABRF makes no express or implied warranties regarding merchantability, fitness for a particular purpose, non-infringement of the intellectual property rights
of third parties, validity and scope of the Licensed Patents, the capability, safety, efficacy, utility or commercial application or usefulness for any purpose of the Licensed Patents, or that it will not grant licenses to one or more Third Parties
to make, use or sell products or perform processes that may be similar to and/or compete with any Licensed Product. 
 10.4 No Obligation of UABRF.
UABRF has no obligation to: 
  

	 	(a)	supervise, monitor, review or otherwise assume responsibility for the production, manufacture, testing, marketing, sale or disposition of any Licensed Product; 

 

	 	(b)	furnish any knowhow or other information relating to the Licensed Patents, other than as specifically provided in this Agreement; or 

 

	 	(c)	bring or prosecute legal action against any Person for infringement of the Licensed Patents. 

ARTICLE 11 

LIABILITY AND INDEMNIFICATION 

11.1 No Liability of UABRF. Neither UABRF nor any of its Representatives have any liability whatsoever to the Licensee, or any Sublicensee or any
Person for or on account of any injury, loss or damage of any kind or nature, sustained by, assessed or asserted against, or any other liability incurred by or imposed upon the Licensee, or any Sublicensee or any Person, resulting from: 

 

	 	(a)	the use of the Licensed Patents by the Licensee or any Sublicensee of the Licensee during the Term; 

  

	 	(b)	the production, use, practice, lease, or sale of any Licensed Product by the Licensee or any Sublicensee during the Term; 

  

	 	(c)	any advertising or other promotional activities with respect to (a) and/or (b) above by the Licensee or any Sublicensee of the Licensee during the Term; or 

 

	 	(d)	the Licensee’s compliance with, and performance of the Licensee’s representations and warranties given under, and the Licensee’s obligations pursuant to, this Agreement. 

  
 19 of 27 

 Confidential Treatment Requested 

 

 11.2 Indemnification by the Licensee. The Licensee agrees to indemnify and hold UABRF and its
Representatives harmless from and against any and all claims, demands, losses, costs, expenses, deficiencies, liabilities or causes of action of any kind or nature (including, without limitation, reasonable attorneys’ fees and other costs and
expenses of defense) resulting from: 
  

	 	(a)	the use of the Licensed Patents during the Term by the Licensee or any Sublicensee of the Licensee; 

  

	 	(b)	the production, use, practice, lease, or sale of any Licensed Product by the Licensee or any Sublicensee of the Licensee during the Term; 

 

	 	(c)	any advertising or other promotional activities with respect to (a) and/or (b) above by the Licensee or any Sublicensee of the Licensee during the Term. 

ARTICLE 12 

MISCELLANEOUS 
 12.1
Entire Agreement. This Agreement is the sole and entire agreement by and between the Parties regarding the subject matter set forth in this Agreement, and this Agreement supersedes all prior agreements and understandings with respect thereto.
All previous negotiations, statements and preliminary instruments by the Parties with respect to the subject matter hereof are merged in this Agreement. 

12.2 No Inducement, Each Party hereby acknowledges that in executing this Agreement, such Party has not been induced, persuaded or motivated by any
promise or representation made by any other Party, unless expressly set forth in this Agreement. 
 12.3 Independent Contractors. The relationship
between the Parties is that of independent contractors. No Party has the authority to bind or act on behalf of the other Party without obtaining such other Party’s prior written consent. The Parties do not intend to create an employer/employee
relationship. 
 12.4 No Third Party Beneficiaries. This Agreement is entered into by and among the Parties for the exclusive benefit of the Parties
and permitted assignees. This Agreement is expressly not intended for the benefit of any creditor of a Party, or any other person. Except and only to the extent provided by applicable statute, no such creditor or Third Party shall have any rights
under this Agreement or any other agreement between the Parties. 
 12.5 Assignment. Neither Party shall sell, assign, transfer or otherwise dispose
of this Agreement including by operation of law to a Third Party without the prior written consent of the other, which consent shall not be unreasonably withheld. Any attempted assignment of this Agreement not in compliance with the terms of this
subsection will be null and void. No assignment will relieve any Party of the performance of any accrued obligation that such Party may then have pursuant to this Agreement. 

12.6 Amendments. Any and all modifications to this Agreement shall only be effective and binding if in writing and signed by a duly authorized
representative of each Party. 

  
 20 of 27 

 Confidential Treatment Requested 

 

 12.7 Notices. Any notice, request, approval or consent required to be given under this Agreement will
be sufficiently given if in writing and delivered to a Party in person, by recognized overnight courier or mailed in the United States Postal Service, postage prepaid to the address appearing below such Party’s signature on the last page of
this Agreement, or at such other address as each Party so designates in accordance with these criteria. Notice shall be deemed effective upon receipt if delivered in person or by overnight courier or five (5) business days after mailing with
the United States Postal Service. 
 12.8 Disputes. 
  

	 	(a)	Equitable Relief. Either Party may seek equitable and legal relief in the event of a breach or threatened breach by the other Party of its obligations under this Agreement, without the requirement to post
a bond. 

  

	 	(b)	Internal Resolution. In the event of any dispute arising out of or relating to this Agreement or to a breach thereof, including its interpretation, performance or termination, the Parties shall try to
settle such conflicts amicably between themselves. In the event that the conflict is not resolved within sixty (60) days after one Party notifies the other Party in writing concerning a dispute or conflict, then the dispute or conflict shall be
referred to executive officers of each Party involved for resolving by negotiation in good faith as soon as practicable but no later than sixty (60) days after its referral. 

 

	 	(c)	Mediation. In the event the Parties are still unable to resolve the dispute or conflict by negotiation, the dispute or conflict may then be submitted by a Party to a mediator, mutually agreed to by the
Parties, for nonbinding mediation. The Parties shall cooperate with the mediator in an effort to resolve such dispute. 

  

	 	(d)	Arbitration. If the dispute is not resolved within sixty (60) days of its submission to the mediator, either Party may submit the dispute for binding arbitration. The arbitration shall be conducted by
three (3) arbitrators, one to be appointed by UABRF, one to be appointed by the Licensee and the third to be appointed by the other two arbitrators. The arbitration shall be conducted in accordance with the commercial rules of the American
Arbitration Association, which shall administer the arbitration. The arbitration, including the rendering of the award, shall take place in Birmingham, Alabama and shall be the exclusive forum for resolving such dispute. The decision of the
arbitrators shall be final and binding upon the Parties and the expense of the arbitration, including, without limitation, the award of attorneys’ fees to the prevailing Party, shall be paid as the arbitrators determine. 

12.9 Rights and Remedies. The rights and remedies provided by this Agreement are cumulative and the use of any one right or remedy by any Party shall
not preclude or waive the right to use any or all other remedies. Such rights and remedies are given in addition to any other rights the Parties may have by law, statute, ordinance or otherwise. 

  
 21 of 27 

 Confidential Treatment Requested 

 

 12.10 Waiver. No waiver of a provision, breach or default shall apply to any other provision or
subsequent breach or default or be deemed continuous, nor will any single or partial exercise of a right or power preclude any other further exercise of any rights or remedies provided by law or equity. 

12.11 Severability. In the event that any covenant, condition, or other provision contained in this Agreement is determined to be invalid, void or
illegal, such covenant, condition or other provision shall be deemed deleted from the Agreement and shall not affect the validity of the remaining provisions of this Agreement. 

12.12 Force Majeure. Neither Party shall be liable for any failure to perform as required by this Agreement to the extent such failure to perform is
due to circumstances reasonably beyond such Party’s control, including, without limitation, labor disturbances or labor disputes of any kind; accidents; acts, omissions or delays in acting by any Governmental Authority; civil disorders;
insurrections; riots; war; acts of war (whether war be declared or not); terrorism; acts of aggression; acts of God; fire; floods; earthquakes; natural disasters; energy or other conservation measures imposed by law or regulation; explosions;
failure of utilities; mechanical breakdowns; material shortages; disease or other such occurrences; provided that the affected Party uses reasonable efforts to overcome or avoid the effects of such cause and continues to perform its obligations to
the extent possible. 
 12.13 Survivability. All rights and obligations of the Parties which by intent or meaning have validity beyond or by their
nature apply or are to be performed or exercised after the termination or expiration of this Agreement shall survive the termination or expiration of this Agreement for the period so specified, if any, or for perpetuity. 

12.14 Governing Law. This Agreement, and the application or interpretation hereof, shall be governed exclusively by its terms and by the laws of the
State of Alabama. 
 12.15 Jurisdiction. The Licensee consents to the personal jurisdiction of the federal and state courts located in the State of
Alabama with respect to all claims or other causes of action arising out of this Agreement. 
 12.16 Interpretation. Whenever used in this Agreement
and when required by the context, the singular number shall include the plural and the plural the singular. Pronouns of one gender shall include all genders, masculine, feminine and neuter. 

12.17 Captions. The captions as to contents of particular sections or paragraphs contained in this Agreement are inserted for convenience and are in no
way to be construed as part of this Agreement or as a limitation on the scope of the particular sections or paragraphs to which they refer. 
 12.18
Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed an original but all of which shall constitute one and the same instrument. 

The remainder of this page intentionally left blank 

  
 22 of 27 

 Confidential Treatment Requested 

 

 IN WITNESS WHEREOF, the Licensee and UABRF have each caused its duly authorized representative to
execute this Agreement, effective as of the Effective Date. 
  

									
	UABRF:	 		 	THE LICENSEE:
	The UAB Research Foundation	 		 	Vaxin Inc.
					
	By:	 	 /s/ Kathy Nugent
	 		 	By:	 	 /s/ William Enright

	Name:	 	 Kathy Nugent
	 		 	Name:	 	 William Enright

	Title:	 	 Managing Director
	 		 	Title:	 	 President & CEO

  

			
	 Address For Notices:
	  	 Address For Notices:

	The UAB Research Foundation	  	Vaxin Inc.
	Attention: The Chief Executive Officer	  	Attention: Bill Enright
	701 20th Street South, AB 770	  	19 Firstfield Road
	Birmingham, Alabama 35233	  	Suite 200
		  	Gaithersburg, MD 20878

  
 23 of 27 

 Confidential Treatment Requested 

 

 EXHIBIT A 

LICENSED PATENTS 
  

											
	 Title
	    	 Country
	    	 Serial #/patent

# /publication #
	    	 Filing

Date
	  	 Notes
	    	 Status

		    	 US PRV
	    	60/055,520	    	8/13/1997	  		    	Expired
		    	 US PRV
	    	60/075,113	    	2/11/1998	  		    	Expired
	Vaccination by topical application of genetic vectors	    	PCT	    	WO 1999/08713	    	8/13/1998	  		    	Completed
	Vaccination by topical application of genetic vectors	    	US	    	6,706,693	    	1/3/2000	  		    	Granted
		    	AU	    	737717	    	8/13/1998	  		    	Granted
		    	EP	    	1015035	    	8/13/1998	  	Validated in FR; DE; NL and UK	    	Granted
		    	HK	    	HK1032753	    	8/13/1998	  		    	Granted
		    	JP	    	2014-42647	    	8/13/1998	  		    	Pending
		    	KR	    	7001342/2008	    	8/13/1998	  		    	Pending
		    	MX	    	268619	    	8/13/1998	  		    	Granted
						
		    	 US PRV
	    	60/132,216	    	5/3/1999	  		    	Expired
	Noninvasive genetic immunization, expression products therefrom and uses thereof	    	US	    	6,716,823	    	3/23/2000	  		    	Granted
	Noninvasive genetic immunization, expression products therefrom and uses thereof	    	US	    	6,348,450	    	5/3/2000	  		    	Granted
	Noninvasive genetic immunization, expression products therefrom and uses thereof	    	PCT	    	WO 00/66179	    	5/3/2000	  		    	Completed
		    	 AU
	    	2009201834	    	5/3/2000	  		    	Pending
		    	 AU
	    	2013260710	    	5/3/2000	  		    	Pending
		    	 CN
	    	ZL00809962.6	    	5/3/2000	  		    	Granted
		    	 EP
	    	1181057	    	5/3/2000	  	Validated in FR; DE; IT, NL; ES and UK	    	Granted
		    	 HK
	    	HK03101756.9	    	5/3/2000	  		    	Granted

  
 24 of 27 

 Confidential Treatment Requested 

 

											
	Vaccination and vaccine and drug delivery by topical application of vectors and vector extracts recombinant vectors, and noninvasive genetic immunization, expression products therefrom, and uses thereof	    	 PCT
	    	WO 2003/070920	    	1/17/2003	    		    	Completed
		    	 HK
	    	HK1071161	    	1/17/2003	    		    	Granted
	Vaccine and drug delivery by topical application of vectors and vector extracts	    	 US
	    	13/961,439	    	8/7/2013	    		    	Pending

  
 25 of 27 

 Confidential Treatment Requested 

 

 EXHIBIT B 

DEVELOPMENT AND COMMERCIALIZATION PLAN 

DEVELOPMENT AND COMMERCIALIZATION PLAN 

Anthrax projected development timeline and milestones: 
  

	 	•	 	[****] 

 Flu projected development timeline and milestones: 

 

	 	•	 	[****] 

  
 ****
Confidential treatment requested 

  
 26 of 27 

 Confidential Treatment Requested 

 

 EXHIBIT C 

FORM OF ROYALTY REPORT 
  

			
	Licensee:
                                         
   	  	Agreement No.:         
	Inventor:
                                         
   	  	P#: P            
	Period Covered: From:     /     / 2008	  	Through:     /     /20    
	Prepared By:         	  	Date:                     
	Approved By:         	  	Date:                     

 If license covers several major product lines, please prepare a separate report for each line. Then combine all product lines
into a summary report. 
  

									
	Report Type:	 	Single Product Line Report:	 	 
		
		 	Multiproduct Summary Report. Page 1 of      Pages
		
		 	Product Line Detail. Line:              Trade name:             
Page:                     

 

					
	Report Currency:	  	U. S. Dollars    Other	 	 

  

																									
	 	  	Gross
Sales	 	  	* Less:
Allowances	 	  	Net
Sales	 	  	Royalty
Rate	 	  	Period Royalty Amount	 
	 Country
	  	  	  	  	  	This Year	 	  	Last Year	 
	 U.S.A.
	  				  				  				  				  				  			
	 Canada
	  				  				  				  				  				  			
	 Europe:
	  				  				  				  				  				  			
		  				  				  				  				  				  			
		  				  				  				  				  				  			
		  				  				  				  				  				  			
		  				  				  				  				  				  			
	 Japan
	  				  				  				  				  				  			
	 Other:
	  				  				  				  				  				  			
		  				  				  				  				  				  			
		  				  				  				  				  				  			
		  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 
	 TOTAL:
	  				  				  				  				  				  			
		  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 

 Total Royalty:
                     Conversion Rate:
                     Royalty in U.S. Dollars: $         

The following royalty forecast is non-binding and for UABRF’s internal planning purposes only: 

Royalty Forecast under This Agreement: 
 Q1:
                     Q2:
                     Q3:
                     Q4:
                     

  
 27 of 27EX-10.9

 Exhibit 10.9 

First Amendment to Amended and Restated Exclusive License Agreement 

This First Amendment to Amended and Restated Exclusive License Agreement (this “First Amendment”) is made effective as of
October 16, 2015 (the “First Amendment Effective Date”) by and between Altimmune, Inc. (f/k/a Vaxin Inc.), a (“Licensee”) and The UAB Research Foundation, a non-profit 501(c)(3) corporation incorporated in the State of
Alabama and an affiliate of UAB (“UABRF”). Company and UABRF may be each individually referred to as a “party” and collectively, the “parties”. 

RECITALS 
 WHEREAS,
Company and UABRF previously entered into that certain Amended and Restated Exclusive License Agreement dated effective as of June 2, 2014 (“Agreement”); and 

WHEREAS, the parties wish to amend Section 9.3 of the Agreement. 

NOW, THEREFORE, for good and valuable consideration, the Parties agree to amend the Agreement as follows: 

AGREEMENT 
 1. All
capitalized terms used herein shall bear the meaning ascribed to them in the Agreement unless otherwise defined herein. 
 2.
Section 9.3(d) of the Agreement is hereby deleted in its entirety and replaced as follows: 
 (d) if by the end of the third (3rd) calendar year after the First Commercial Sale occurred, or by January 1, 2023, whichever comes first, fifty percent (50%) of the minimum royalty payment described in Section 5.8
of this Agreement due in that calendar year is not originating from Net Sales; 
 3. All other terms and conditions of the Agreement shall
remain in full force and effect. 
 [Signatures on following page] 

 IN WITNESS WHEREOF, Company and UABRF have each caused its duly authorized representative to execute this First
Amendment, effective as of the date written above. 
  

							
	UABRF:	  	Company:
	The UAB Research Foundation	  	Altimmune, Inc.
				
	 By: 
	 	 /s/ Kathy Nugent
	  	By: 	 	 /s/ William Enright

							
	 Name: 
	 	Kathy Nugent, Ph.D.	  	Name: 	 	William Enright

							
	 Title: 
	 	Executive Director	 	Title: 	 	President and CEO
		
	Date Signed: 10-16-15	 	Date Signed: 16 October, 2015

  
 2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00273-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00273-of-00352.parquet"}]]